Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

European Medicines Agency Validates Gilead's Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV

Business Wire February 1, 2016

Maybe Some Good News For A Big Biotech ETF

Benzinga.com January 29, 2016

Gilead's John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director

Business Wire January 29, 2016

Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016

Business Wire January 26, 2016

Looking To Healthcare ETFs For Earnings Growth

Benzinga.com January 21, 2016

Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib

Business Wire January 19, 2016

Rethink U.S. Large-Cap Exposure With This ETF

Benzinga.com January 15, 2016

Write A Prescription For This Healthcare ETF

Benzinga.com January 15, 2016

Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib

Business Wire January 13, 2016

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B

Business Wire January 12, 2016

Moving To Momentum With ETFs

Benzinga.com January 12, 2016

Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11

Business Wire January 8, 2016

Merck (MRK) CEO itching to make acquisition deals in pharma space

Canadian Press January 5, 2016

Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis

Business Wire January 5, 2016

Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection

Business Wire January 5, 2016

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection

Business Wire January 4, 2016

Peering Through The Fog To Find The Best Sectors Into Year End

Benzinga.com December 23, 2015

An Award-Winning Debut For This Goldman ETF

Benzinga.com December 23, 2015

Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases

Business Wire December 17, 2015

Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting

Business Wire December 8, 2015